Because albumin is the most abundant serum protein produced by the liver, we reasoned that linking the expression of human PCSK9 to this promoter would induce a dyslipidemia similar to that observed in humans carrying PCSK9 gain-of function mutations [13, 32–37]. This evidence concerns the gene ALB and metabolic syndrome.